Abstract: A seat part for a vehicle seat may have a support structure which has a tubular frame and a composite component. The tubular frame may have at least one opening on a front side. A threaded sleeve may be arranged and the composite component is arranged on the front side of the tubular frame and is secured to the tubular frame via a screw screwed into the threaded sleeve.

Abstract: A seat part for a vehicle seat may have a support structure which has a tubular frame and a composite component. The tubular frame may have at least one opening on a front side. A threaded sleeve may be arranged and the composite component is arranged on the front side of the tubular frame and is secured to the tubular frame via a screw screwed into the threaded sleeve.

Abstract: A composite component (110) for a vehicle seat (1), in particular a motor vehicle seat, having a plurality of fabric layers (116) of a fiber material and a matrix material (118) fixing the fabric layers (116). The outer component contour of the composite component (110) is at least in some sections formed by a fabric strand (125) embedded into the matrix material (118). A vehicle seat (1), in particular a motor vehicle seat, includes a composite component, in particular with a backrest structure (110) designed as the composite component.

Abstract: A composite component (110) for a vehicle seat (1), in particular for a motor vehicle seat, includes a plurality of fabric layers (116) of a fibrous material, a matrix material (118) securing the fabric layers (116), and an insert part (140), disposed between at least two of the fabric layers (116), for locally reinforcing the composite component. An insert strand (150) is disposed at least in sections along an edge or an edge surface (141.1) of the insert part (140). A vehicle seat (1) includes the composite component, in particular with a back structure (110) designed as a composite component.

Abstract: A composite component (110) for a vehicle seat (1), in particular a motor vehicle seat, having a plurality of fabric layers (116) of a fiber material and a matrix material (118) fixing the fabric layers (116). The outer component contour of the composite component (110) is at least in some sections formed by a fabric strand (125) embedded into the matrix material (118). A vehicle seat (1), in particular a motor vehicle seat, includes a composite component, in particular with a backrest structure (110) designed as the composite component.

Abstract: A composite component (110) for a vehicle seat (1), in particular for a motor vehicle seat, includes a plurality of fabric layers (116) of a fibrous material, a matrix material (118) securing the fabric layers (116), and an insert part (140), disposed between at least two of the fabric layers (116), for locally reinforcing the composite component. An insert strand (150) is disposed at least in sections along an edge or an edge surface (141.1) of the insert part (140). A vehicle seat (1) includes the composite component, in particular with a back structure (110) designed as a composite component.

Abstract: This invention relates to a semisolid ophthalmic composition, in particular an ointment, comprising (1) an ophthalmic drug, e.g. a staurosporine derivative, (2) an ointment base and (3) an agent for dispersing and/or dissolving said drug in the ointment base, selected from a poly(ethylene-glycol), a polyethoxylated castor oil, an alcohol having 12 to 20 carbon atoms and a mixture of two or more of said components.

Abstract: Use of a compound of formula (I): wherein the symbol cyclodextrin? ]n represents a n-valent residue derived from a cyclodextrin compound by removing n of its hydroxyl groups; n is a number greater than 0 and represents the average number of substituents of formula per molecule of said compound; h is 0 or 1; R1 is a di-valent group selected from alkylene, hydroxy alkylene, halogeno alkylene, monocyclic aralkylene, cycloalkylene and phenylene; R2, R3 and R4 are each independently of one another a group selected from alkyl, cycloalkyl, aryl, aralkyl, and cycloheteryl; Xm? is a m-fold negatively charged anion; m is an integer being equal or greater than 1; and k is n/m in the preparation of an anti-infective medicament, as preservative and penetration enhancer.

Abstract: The present invention describes in particular a method for stabilizing a pharmaceutical composition by contacting said composition with a polymeric material comprising in particular an ethylene oxide sterilization step.

Abstract: The invention relates to a process for producing photonic crystals by first providing an inorganic photoresist which, on illumination with energy greater than the electronic band gap of the photoresist, exhibits a phase alteration. Illumination of the photoresist with a laser beam whose energy is lower than the electronic band gap of the photoresist but whose intensity at the focal point is so high that nonlinear effects occur there nevertheless results in a phase alteration in the photoresist. Thereafter, the illuminated photoresist is exposed to an etching solution which preferentially dissolves one phase of the photoresist, and the developed photoresist is finally removed therefrom as a photonic crystal. Inorganic photonic crystals produced by the process according to the invention are suitable for completely optical systems, circuits and components for optical telecommunication or computer systems.

Abstract: The present invention relates to a pharmaceutical composition comprising a peranhydrocyclodextrin, a drug and a carrier, to the use of a peranhydrocyclodextrin as a drug transport enhancer (e.g. permeation enhancer), and to the use of a peranhydrocyclodextrin in the preparation of a pharmaceutical composition as a synergistic adjunctive system.

Abstract: Use of a compound of formula (I): wherein the symbol represents a n-valent residue derived from a cyclodextrin compound by removing n of its hydroxyl groups; n is a number greater than 0 and represents the average number of substituents of formula per molecule of said compound; h is 0 or 1; R1 is a di-valent group selected from alkylene, hydroxy alkylene, halogeno alkylene, monocyclic aralkylene, cycloalkylene and phenylene; R2, R3 and R4 are each independently of one another a group selected from alkyl, cycloalkyl, aryl, aralkyl, and cycloheteryl; xm? is a m-fold negatively charged anion; m is an integer being equal or greater than 1; and k is n/m in the preparation of an anti-infective medicament, as preservative and penetration enhancer.

Abstract: The present invention describes in particular a method for stabilizing a pharmaceutical composition by contacting said composition with a polymeric material comprising in particular an ethylene oxide sterilization step.

Abstract: The present invention relates to a pharmaceutical composition comprising a peranhydrocyclodextrin, a drug and a carrier, to the use of a peranhydrocyclodextrin as a drug transport enhancer (e.g. permeation enhancer), and to the use of a peranhydrocyclodextrin in the preparation of a pharmaceutical composition as a synergistic adjunctive system.

Abstract: The present invention relates to a method of protecting copper-sensitive compounds and/or compositions from decomposition.

Abstract: The invention relates to a process for producing photonic crystals by first providing an inorganic photoresist which, on illumination with energy greater than the electronic band gap of the photoresist, exhibits a phase alteration. Illumination of the photoresist with a laser beam whose energy is lower than the electronic band gap of the photoresist but whose intensity at the focal point is so high that nonlinear effects occur there nevertheless results in a phase alteration in the photoresist. Thereafter, the illuminated photoresist is exposed to an etching solution which preferentially dissolves one phase of the photoresist, and the developed photoresist is finally removed therefrom as a photonic crystal. Inorganic photonic crystals produced by the process according to the invention are suitable for completely optical systems, circuits and components for optical telecommunication or computer systems.

Abstract: The invention relates to a process for producing a three-dimensional photonic crystal which consists of a material with high refractive index. To this end, a photonic crystal which consists of a polymer is first provided, through whose surface there are empty interstitial sites. As a result of introduction of a filler into the interstitial sites, a network forms there from the filler. After the removal of the polymer, cavities form in the network formed from the filler, into which the material with high refractive index is introduced, so that a structure of the material with high refractive index forms therein. After the removal of the filler, the structure of the material with high refractive index remains, which can be removed as the photonic crystal which consists of a material with high refractive index. Photonic crystals produced by the process according to the invention have complete band gaps in the region of telecommunications wavelengths.

Abstract: The present invention relates to the use of terguride and proterguride for the prophylaxis and/or the treatment of chronic pain conditions as well as to pharmaceutical compositions comprising terguride and/or proterguride optionally together with an opiate analgesic.

Abstract: The invention relates to a combination of radio waves with pharmacologically active substances chosen from the group: a) monoclonal antibodies and/or b) tyrosine-kinase inhibitors and/or c) angiogenesis inhibitors and/or d) farnesyl-transferase inhibitors and/or e) topoisomerase-I or -II inhibitors and/or f) cytokines and/or g) antisense oligonucleotides. optionally together with one or more chemotherapeutics, as well as to the use of this combination for the prophylaxis and/or treatment of cancer, tumors and metastases.

Abstract: The present invention describes in particular a method for stabilizing a pharmaceutical composition by contacting said composition with a polymeric material comprising in particular an ethylene oxide sterilization step.